Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ENTX
Entera Bio Ltd. (ENTX) Altman Z-score
Entera Bio Ltd.'s Altman Z-score for fiscal 2025 is 6.22, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 6.22 | (11.00) |
| FY2024 | 17.22 | 20.42 |
| FY2022 | −3.20 | (11.16) |
| FY2021 | 7.95 | 15.53 |
| FY2020 | −7.58 | (4.11) |
| FY2019 | −3.47 | (0.70) |
| FY2018 | −2.77 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.82 | — | 0.98 | |
| Retained earnings / total assets | (7.84) | — | −10.97 | |
| EBIT / total assets | (0.72) | — | −2.38 | |
| Market value of equity / total liabilities | 30.99 | — | 18.59 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Safe zone | 6.22 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −20.27 | ||
Z and Z″ put Entera Bio Ltd. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | 10.3× |
| DMAC DiaMedica Therapeutics, Inc. compare | 6.7× |
| ENTX Entera Bio Ltd. | 6.2× |
| ASMB Assembly Biosciences, Inc. compare | 1.1× |
| PRTA Prothena Corporation plc compare | −0.2× |
| EDIT Editas Medicine, Inc. compare | −13.4× |
| TECX Tectonic Therapeutic, Inc. compare | — |
| YDES YD Bio Limited compare | — |
| RZLT Rezolute, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets